Molecular Profile
What Is Retatrutide?
TypeSynthetic peptide
CAS Number2381089-83-2
Molecular Weight4,731 g/mol
Amino Acids39
Fatty Acid ChainA fatty acid attached to extend how long it stays active in your bodyC20 diacid
⚠️ FOR RESEARCH PURPOSES ONLY — This compound is not FDA approved. All data presented is from clinical trials for educational reference.
Triple-Action Weight Loss Compound
GLP-3 (RT)
4.8 (373 reviews)
LY3437943GLP-3
A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research. Premium Research Peptide.
Dosage
Quantity
1
From
$69.99Dosage
Quantity
1
From
$69.99Thu, Apr 9 - Wed, Apr 15
Overnight shipping available
4 interest-free payments of $17.50We accept
GLP-3 (RT)$69.99
Free shippingon orders over $150
60-day money-backguarantee
Secure checkout256-bit SSL
Certificate of Analysis
Third Party Tested by Freedom Diagnostics
Compound Information
Technical specifications
PubChem Database
Storage Requirements
Stability Information
Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)
-20°C•24+ months
Reconstituted
2-8°C•~30 days
Development Status
Where It Stands
Phase 3 ActiveNot FDA Approved
DeveloperEli Lilly
Trial ProgramTRIUMPH
Phase 3 ResultsExpected 2026
Potential Approval~2027
Sources & References
Peer-reviewed research
New England Journal of Medicine
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2023•DOI: 10.1056/NEJMoa2301972
Jastreboff AM, et al.
View Source
The LancetRetatrutide for People with Type 2 Diabetes — A Phase 2 Trial
2023
Rosenstock J, et al.
View Source
Nature MedicineRetatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
2024
Sanyal AJ, et al.
View Source
Lancet Diabetes & EndocrinologyEffects of Retatrutide on Body Composition
2025
Coskun T, et al.
View Source
PubMed CentralTriple Agonism Based Therapies for Obesity
2025
View Source
PubMed CentralRetatrutide — A Game Changer in Obesity Pharmacotherapy
2025
View Source
PubMed CentralEfficacy and Safety of Retatrutide — Systematic Review & Meta-Analysis
2024
View Source
Eli LillyTRIUMPH-4 Phase 3 Trial Results
2025
View Source
Nature Cell DiscoveryStructural Analysis of Incretin Receptor Agonists
2024
View Source
PubChem DatabaseRetatrutide Compound Information
View Source
ClinicalTrials.govRetatrutide Clinical Trials Registry
View Source
⚠️Important Research Notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
